ChemicalBook--->CAS DataBase List--->1310426-33-5

1310426-33-5

1310426-33-5 Structure

1310426-33-5 Structure
IdentificationBack Directory
[Name]

SEP-363856
[CAS]

1310426-33-5
[Synonyms]

SEP-856
Ulotaront
SEP-363856
SEP 363856,SEP363856
5H-Thieno[2,3-c]pyran-7-methanamine, 4,7-dihydro-N-methyl-, (7S)-
[Molecular Formula]

C9H13NOS
[MDL Number]

MFCD34470241
[MOL File]

1310426-33-5.mol
[Molecular Weight]

183.27
Chemical PropertiesBack Directory
[Boiling point ]

291.9±30.0 °C(Predicted)
[density ]

1.123±0.06 g/cm3(Predicted)
[pka]

9.15±0.10(Predicted)
Hazard InformationBack Directory
[Uses]

SEP-363856 (SEP-856), an orally active TAAR1 and 5-HT1A agonist and CNS active psychotropic agent with a unique, non-D2/5-HT2A mechanism of action, exerts its antipsychotic-like effects. SEP-363856 (SEP-856) has the potential for the study of schizophrenia[1].
[in vivo]

SEP-363856 (0.3, 1 and 10 mg/kg, i.p.) is CNS active and exhibits a behavioral signature similar to known antipsychotic drugs[1].
SEP-363856 (0.3, 1 and 10 mg/kg, orally once) significantly reduces PCP-induced hyperactivity[1].
Oral SEP-363856 administration (1, 3 and 10 mg/kg) produces a dosedependent decrease in REM sleep, increase in latency to REM sleep and increase in cumulative wake (W) time[1].

Animal Model:Acute treatment with phencyclidine (PCP), which induces robust hyperactivity in rodents[1].
Dosage:0.3, 1 and 3 mg/kg.
Administration:Orally once.
Result:Resulted in a dose-dependent inhibition of PCP-induced hyperactivity responses in C57Bl/6J mice (1-way ANOVA F (5, 59) = 18.96, p < 0.0001; Tukey’s post-hoc test, p < 0.05) with a 50% effective dose (ED50) of approximately 0.3 mg/kg.
Animal Model:Male Sprague Dawley rats[1].
Dosage:1, 2, and 5 mg/kg.
Administration:I.V. injection. (Pharmacokinetic Analysis).
Result:0.5 hours in mice and rats and maximum plasma concentrations reached within 6 ± 2.83 hours in monkeys.
Penetrated mouse and rat brains after oral administration (10 mg/kg), with average brain-to-plasma AUC ratios of ~3 respectively.
[IC 50]

TAAR1: 0.140 μM (EC50); 5-HT1A Receptor: 2.3 μM (EC50); 5-HT1B Receptor: 15.6 μM (EC50); 5-HT1D Receptor: 0.262 μM (EC50); 5-HT2A Receptor: >10 μM (EC50); 5-HT2C Receptor: 30 μM (EC50); 5-HT7 Receptor: 6.7 μM (EC50)
[References]

[1] Dedic N, et al. SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Action. J Pharmacol Exp Ther. 2019 Oct;371(1):1-14. DOI:10.1124/jpet.119.260281
1310426-33-5 suppliers list
Company Name: ShangHai Caerulum Pharma Discovery Co., Ltd.  
Telephone: 18149758185 18149758185
Website: www.caerulumpharma.com
Company Name: Z IntellecChem & Tech. Co., Ltd  
Telephone: 13179383568; 15050866711
Website: http://www.zzhxchem.com/
Company Name: Wuhan chuang he chemical co. LTD  
Telephone: 15907120073
Website: https://www.chemicalbook.com/ShowSupplierProductsList89338/0_EN.htm
Company Name: JinOu Biomedical (Nanjing) Co., Ltd.  
Telephone: 13000000000
Website: www.chemicalbook.com/ShowSupplierProductsList1596079/0_EN.htm
Company Name: TargetMol Chemicals Inc.  
Telephone: 4008200310 15002144251
Website: https://www.targetmol.cn/
Company Name: Suzhou Haiben Pharmaceutical Co., Ltd  
Telephone: 19353112242
Website:
Company Name: Shandong Dayou Pharmaceutical Research and Development Co., Ltd.  
Telephone: dayouchem@126.com 15165037910
Website:
Tags:1310426-33-5 Related Product Information
156223-05-1 14173-40-1 163521-12-8 913611-97-9 74050-98-9 50-67-9